The Longevity Industry Is Selling You Something. Ask for the Evidence First.

Read Time: 6 min

Somewhere between the full-body scan clinic opening near me in New York City and the high-protein bar staring at me from the checkout counter at my local grocery store, I began to notice a pattern. The longevity industry — and it is very much an industry, with investors, influencers, and an increasingly devoted consumer base — has found a remarkably effective formula: take a genuine scientific question about human aging, attach it to a product or service, market it with the vocabulary of evidence-based medicine, and price it in a way that signals exclusivity and seriousness. What the formula consistently omits is the part where the product is actually proven to work.

Consider the recent news that Daniel Ek, the founder of Spotify, has launched a company centered on full-body imaging and plans to open his first clinic in New York City. The concept is marketed as “a health check for your future self” — language that is reassuring, aspirational, and almost entirely devoid of clinical specificity. The price for this particular vision of the future has not yet been announced, but Ek’s company will be entering a market where competitors already charge close to $4,000 for similar scans. The central question that price tag raises — whether full-body imaging in asymptomatic, healthy adults actually improves health outcomes, or whether it primarily generates incidental findings that lead to further testing, anxiety, and procedures of uncertain benefit — receives considerably less attention in the marketing materials than the sleek clinic design.

Protein, Influence, and the Limits of Expertise

The protein conversation offers an equally instructive case study in how longevity claims travel from hypothesis to consumer product with minimal evidentiary friction along the way. Walk into virtually any grocery store, restaurant, or coffee shop in an American city today and you will encounter products prominently labeled as packed with protein, positioned as essential tools for health and longevity. Cardiologist Eric Topol and former National Institutes of Health nutrition researcher Kevin Hall have both written extensively about the absence of strong evidence for high-protein diets as a longevity intervention, noting that the average American already consumes all the protein their body can safely use.

Physician and bestselling author Peter Attia has argued the opposite — that Americans should consume roughly double the standard recommended daily allowance of protein, at 1.6 grams per kilogram of body weight rather than the standard 0.8. Attia has been serving simultaneously as an investor in and chief science adviser to David Protein, a company selling high-protein, low-sugar supplement bars. He has also described himself as “neither a primary care physician nor a provider of concierge care,” while reportedly charging between $100,000 and $500,000 per year for personalized longevity advice.

The financial entanglements in this space extend well beyond any single practitioner. According to a report from the consumer advocacy group Public Citizen, surgeon general nominee Dr. Casey Means — who, like Attia, never completed residency training — has extensive financial connections to companies marketing basil seeds, algae, and a protein powder found to contain significant lead contamination, many of which have not been fully disclosed. The pattern across these cases is consistent: prominent longevity practitioners with genuine public platforms, financial interests in the products they recommend, and incomplete transparency about those interests, operating in a regulatory environment that has not yet developed adequate disclosure standards for physician-influencers.

Correspondence With Epstein Reveals the Shape of Elite Longevity Care

The correspondence between Attia and Jeffrey Epstein, reported recently by the New York Times, provides an unusual window into what wealthy clients actually receive when they pay for personalized longevity medicine. The documents include records of blood tests covering a wide range of analytes that no primary care physician would routinely order for a healthy patient, as well as prescriptions for metformin, a first-line diabetes treatment that some researchers believe may have anti-aging properties, though the evidence for that application in non-diabetic patients remains preliminary. The correspondence is notable less for any individual intervention than for what it reveals about the structure of elite longevity care: extensive, expensive, highly personalized testing and prescribing that runs well ahead of what the published evidence would support for a general population.

The longevity industry will continue growing, because the underlying desire it serves — to live longer and feel better — is entirely legitimate, and because the scientific questions it engages with are genuinely interesting. What it requires, from consumers and regulators alike, is the same standard of scrutiny we would apply to any other medical intervention: rigorous evidence, transparent conflicts of interest, and honest communication about what is known and what remains speculative. A $4,000 scan and a $500,000 annual retainer deserve at least as much evidentiary accountability as a drug seeking FDA approval. The marketing budgets suggest otherwise, but the science does not change to accommodate the price tag.